Your browser doesn't support javascript.
loading
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
Achiron, Anat; Mandel, Mathilda; Dreyer-Alster, Sapir; Magalashvili, David; Menascu, Shay; Warszawer, Yehuda; Dolev, Mark; Didikin, Maria; Harari, Gil; Sonis, Polina; Falb, Rina; Gurevich, Michael.
  • Achiron A; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.. Electronic address: Anat.achiron@sheba.health.gov.il.
  • Mandel M; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel.
  • Dreyer-Alster S; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel.
  • Magalashvili D; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel.
  • Menascu S; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Warszawer Y; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel.
  • Dolev M; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Didikin M; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel.
  • Harari G; School of Public Health, University of Haifa, Israel.
  • Sonis P; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel.
  • Falb R; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel.
  • Gurevich M; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Mult Scler Relat Disord ; 72: 104616, 2023 Apr.
Article en En | MEDLINE | ID: mdl-36933299

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 / Esclerosis Múltiple Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 / Esclerosis Múltiple Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article